ESMO Asia 2023 | KEYNOTE-522: optimal preoperative IO and residual disease management in TNBC

Michail Ignatiadis, MD, PhD, Institut Jules Bordet and Université Libre de Bruxelle, Brussels, Belgium, outlines unanswered questions from the Phase III KEYNOTE-522 trial (NCT03036488), which investigated neoadjuvant pembrolizumab with chemotherapy, the current standard of care in early TNBC. These remaining questions refer to the efficacy of PD-1 inhibitors in comparison with PD-L1 inhibitors, identification of the most suitable chemotherapy to pair with immunotherapy and whether identification of patients that are unlikely to benefit from neoadjuvant pembrolizumab is possible. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.